Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
- H. Doehner, E. Estey, +16 authors C. Bloomfield
- Medicine
- Blood
- 21 January 2010
In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable… Expand
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
- M. Slovak, K. Kopecky, +9 authors F. Appelbaum
- Medicine
- Blood
- 2000
The associations of cytogenetics with complete remission (CR) rates, overall survival (OS), and outcomes after CR were studied in 609 previously untreated AML patients younger than 56 years old in a… Expand
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
- P. Mcsweeney, D. Niederwieser, +21 authors R. Storb
- Medicine
- Blood
- 1 June 2001
Toxicities have limited the use of allogeneic hematopoietic cell transplantation (HCT) to younger, medically fit patients. In a canine HCT model, a combination of postgrafting mycophenolate mofetil… Expand
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
- C. Leith, K. Kopecky, +8 authors C. Willman
- Biology, Medicine
- Blood
- 1 August 1999
Therapeutic resistance is a major obstacle in the treatment of acute myeloid leukemia (AML). Such resistance has been associated with rapid drug efflux mediated by the multidrug resistance gene 1… Expand
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
- A. List, K. Kopecky, +9 authors F. Appelbaum
- Medicine
- Blood
- 1 December 2001
Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated cellular export of anthracyclines at clinically achievable concentrations. This randomized controlled trial was performed to test the… Expand
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
- M. Slovak, K. Kopecky, +9 authors F. Appelbaum
- Medicine
- 15 December 2000
The associations of cytogenetics with complete remission (CR) rates, overall survival (OS), and outcomes after CR were studied in 609 previously untreated AML patients younger than 56 years old in a… Expand
Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.
- K. Sullivan, P. Weiden, +7 authors C. Badger
- Medicine
- Blood
- 1 May 1989
To assess the influence of graft-versus-host disease (GVHD) on recurrent leukemia and survival after allogeneic marrow transplantation, we studied 1,202 patients with acute nonlymphocytic leukemia… Expand
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
- E. Sievers, F. Appelbaum, +6 authors I. Bernstein
- Medicine
- Blood
- 1 June 1999
Leukemic blast cells express the CD33 antigen in most patients with acute myeloid leukemia (AML), but this antigen is not expressed by hematopoietic stem cells. We conducted a study to determine… Expand
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the…
Because there are differing opinions regarding treatment of patients in the chronic phase of chronic myeloid leukemia (CML), the American Society of Hematology convened an expert panel to review and… Expand
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.
- D. Stirewalt, K. Kopecky, +4 authors J. Radich
- Biology, Medicine
- Blood
- 1 June 2001
The prevalence and significance of genetic abnormalities in older patients with acute myeloid leukemia (AML) are unknown. Polymerase chain reactions and single-stranded conformational polymorphism… Expand